TacticScaleWhat Innovent Biologics Does & How It Makes Money (1801.HK)
Updated October 2026 · reflects Innovent Biologics's latest reported financials
Chinese biotech developing and selling antibody drugs for cancer and chronic diseases. It makes most of its money selling its own and in-licensed commercial drugs, mainly in China, such as the cancer immunotherapy TYVYT.
How Innovent Biologics makes money
It makes most of its money selling its own and in-licensed commercial drugs, mainly in China, such as the cancer immunotherapy TYVYT. It also earns revenue from distributing pharmaceutical products and from consultation and R&D services.
What Innovent Biologics does
Innovent Biologics is a Suzhou-based biopharmaceutical company, founded in 2011, that discovers, develops, manufactures and commercializes monoclonal antibodies and other drugs. It focuses on oncology, ophthalmology, autoimmune, cardiovascular and metabolic diseases, and operates in China, the United States, Europe and other markets. Its commercial portfolio is broad. It includes its own and partnered drugs such as the PD-1 inhibitor TYVYT (sintilimab), the biosimilars BYVASDA, SULINNO and HALPRYZA, the CAR-T therapy FUCASO, and the metabolic drug mazdutide. It also sells in-licensed products such as Cyramza, Retsevmo, Jaypirca and PEMAZYRE. Besides drug sales, it distributes pharmaceutical products and offers consultation and R&D services.
Products & services
- TYVYT (sintilimab)
- BYVASDA (bevacizumab)
- SULINNO (adalimumab)
- FUCASO (equecabtagene autoleucel)
- mazdutide
- DOVBLERON (taletrectinib)
What is Innovent Biologics worth?
A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.
We show a fair value only when the method is trustworthy. See Innovent Biologics on TacticScale →
Related companies
InventisBio (688382.SS) · Bio-Thera Solutions (688177.SS) · Innoviva (INVA)